Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma

Table 7 Co-expression of FN and αvβ3 and osteosarcoma patient survival based on multivariate analysis

Characteristics	Comparison	Disease-free survival (months)			Overall survival (months)
Characteristics	Comparison	HR	95%CI	P value	HR	95%CI	P value
FN⁺/αvβ3⁺	vs. others^a	2.66	1.13–6.23	0.025	3.75	1.36–10.36	0.011
Tumor size (cm)	< 5 vs. ≥ 5	2.55	1.06–6.14	0.036	2.57	0.72–9.24	0.147
Enneking staging	I-IIA vs. IIB	3.34	1.20–9.28	0.021	2.90	0.60–13.87	0.184
Response to chemotherapy	Good vs. poor	0.75	0.30–1.84	0.526	0.48	0.12–1.99	0.309
C-index (95%CI)		0.75	0.65–0.86		0.84	0.70–0.97
FN⁺/αvβ3⁺	vs. FN⁻/αvβ3⁻	5.62	1.91–16.52	0.002	6.35	1.54–26.14	0.010
FN⁺/αvβ3⁻ plus FN⁻/αvβ3⁺	vs. FN⁻/αvβ3⁻	3.79	1.50–9.54	0.005	2.31	0.59–8.96	0.228
Tumor size (cm)	< 5 vs. ≥ 5	2.04	0.84–4.93	0.115	2.39	0.67–8.56	0.182
Enneking staging	I-IIA vs. IIB	3.46	1.22–9.77	0.019	2.69	0.55–13.08	0.220
Response to chemotherapy	Good vs. poor	1.08	0.41–2.79	0.882	0.62	0.14–2.80	0.536
C-index (95%CI)		0.79	0.69–0.90		0.85	0.71–0.98

HR hazard ratio, CI confidence interval
⁺High expression; ⁻low/negative expression; ^aFN⁺/αvβ3⁻ plus FN⁻/αvβ3⁺ plus FN⁻/αvβ3⁻

ISSN: 1477-7819